To: NATIONAL EDITORS Contact: Robert Zirkelbach of America's Health Insurance Plans, +1-202-778-8493
..., water and coastal resources, public health and waste sector ((Begum et al., 2011a). Climate c... of the parasite in the mosquito (National Research Council, 2001). Both vector (i.e., female...In addition to direct expenditures on prevention and treatment of malaria, households...
To: NATIONAL EDITORS Contact: Robert Zirkelbach of AHIP, +1-202-778-8493
The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. This request identifies the estimated reporting burden associated with the reporting of CDBG-R assisted activities as they are completed and closing out the CDBG-R program. The American Recovery and Reinvestment Act of 2009 (Recovery Act) appropriated $1 Billion in Community Development Block Grant (CDBG) funds to states and local governments that received CDBG funding in Fiscal Year 2008 to carry out, on an expedited basis, eligible activities under the CDBG program. The purpose of the CDBG-R funding was to stimulate the economy through...
... educational opportunities and access to health care. All CDBG-R funds were required to be expende...While the CDBG-R expenditure deadline has passed, all CDBG-R assisted activitie...Once CDBG-R assisted activities meet a national objective and are physically complete, grantees ma...
The paper attempts to examine the socio-economic determinants of life expectancy for 91 developing countries using multiple regression and probit frameworks. Disaggregated probit regression has been applied for three groups of countries with low, medium and high life expectancy. Most of explanatory variables turned out to be statistically insignificant, which imply that relevant socio-economic factors like per capita income, education, health expenditure, access to safe water, and urbanization cannot always be considered to be influential in determining life expectancy in developing countries. Based on the analyses it has been suggested that the countries should formulate and implement appropriate social sector policies and programs to increase physicians' availability, and reduce adult...
..., which worked mainly through impact of national income on the poor's income and public expenditure...
... capita amount of prescription drug expenditures (as determined based on the most recent National T...
... the efficiency of government expenditures, and the sustainability of fiscal policies in term... Additionally, negotiations for achieving national goals such as complying with European fiscal polic... is especially significant in the area of health and social services on the federal level, and wast...
... and Other Drug Treatment Services National Minimum Data Set - The purpose of this Review of t.... Australian health expenditure by remoteness: a comparison of remote, regional an...
MOUNTAIN VIEW, Calif., July 18, 2012 /PRNewswire/ -- The U.S. clinical laboratory market is on the cusp of radical changes, but it is unclear if these transitions will bring greater prosperity to the market or dampen its growth prospects. The market is assessing the impact of developments like Accountable Care Organizations (ACOs) and Food and Drug Administration (FDA) oversight on laboratory developed tests (LDTs). Further, the market is witnessing physician migration to hospitals, continued consolidation of laboratories and hospitals, increased connectivity among all healthcare providers, and changes to current procedural terminology (CPT) coding in molecular pathology. New analysis from Frost & Sullivan's (http:// www.drugdiscovery.frost.com) Analysis of the U.S. Clinical Laboratory ...
WASHINGTON - Marylanders continue to spend more on prescription drugs compared to their national counterparts, despite the state's lower overall health care spending, according to an analysis of state and national health care expenditure data. Each Marylander spent about $1,000 for prescription drugs in 2007, 33 percent more than the national average of about $750. The state's per capita spending on health care was about $6,400, 14 percent lower than the national average of about $7,500.
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2013, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other interesting searches:
Legal basis | jharkhand public service commission | Customers | owens illinois glass company | Since Israel | dictamen pericial en materia penal | oligopole de paix | garantias individuales articulos | grade police | domingo montes
